Kinnate Biopharma Inc.
12707 High Bluff Drive
Suite 200
San Diego
CA
92130
United States
53 articles with Kinnate Biopharma Inc.
-
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
3/15/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the year ended December 31, 2022, and recent corporate updates.
-
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
3/14/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”) today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla.
-
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
2/21/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that it has acquired ownership stake of Kinnjiu Biopharma Inc. (“Kinnjiu”) previously held by the Series A investors using a combination of Kinnate shares and cash.
-
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
2/14/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248.
-
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
2/6/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. ET / 10:40 a.m. PT.
-
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
1/26/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023.
-
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
1/17/2023
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences.
-
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
11/10/2022
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the quarter ended September 30, 2022, and recent corporate updates.
-
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
10/11/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoing global Phase 1 KN-8701 trial evaluating KIN-2787, an investigational pan-RAF inhibitor, in patients with BRAF-altered solid tumors and/or who have NRAS mutant melanoma.
-
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor
9/21/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-RAF inhibitor, KIN-2787, for treatment of patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive stage IIb to IV malignant melanoma that is metastatic or unresectable.
-
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit
9/15/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.
-
Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference
8/30/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Friday, September 9 at 9:10 AM ET.
-
Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates
8/11/2022
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the quarter ended June 30, 2022, and recent corporate updates.
-
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/2/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the “Bullseye - Targeted Oncology - Quanta of Targets” panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 10:20 a.m. ET.
-
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences - June 01, 2022
6/1/2022
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced that the company will participate in two upcoming in-person investor conferences.
-
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
5/26/2022
Kinnate Biopharma Inc. announced the presentation of the design and rationale of a Phase 1 trial-in-progress evaluating the Company’s pan-FGFR inhibitor product candidate, KIN-3248.
-
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
5/12/2022
Kinnate Biopharma Inc. announced financial results for the quarter ended March 31, 2022.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
4/18/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248.
-
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
4/8/2022
Kinnate Biopharma Inc. announced that it will present data from the company’s lead RAF kinase inhibitor program, KIN-2787, and its clinico-genomics study investigating the occurrence of BRAF Class II and Class III alterations across solid tumors.